Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05157126

Gentamicin Open Tibia Study

Local application of antibiotics directly to the traumatic wound is a promising treatment for the prevention of infection after open tibia fractures, which are a significant source of disease burden globally, particularly in low-income countries. This study aims to measure the effect of locally applied gentamicin on risk of infection for open tibial fractures in Tanzania. If proven effective, local gentamicin would be a highly cost-effective strategy to reduce complications and disability from open tibial fractures that could impact care in both high- and low-income countries.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Muhimbili Orthopaedic Institute

Dar es Salaam, Tanzania

Location status: Recruiting

Location contact

Billy T Haonga, MD

CONTACT

255-022-2151298

Billy T Haonga, MD

PRINCIPAL_INVESTIGATOR

About this study

Tibial shaft (shinbone) fractures are the most common major fracture of the lower leg and are frequently associated with a break in the skin known as an open fracture. Because the bone is exposed by the open wound, open tibial fractures are often complicated by infection and failure of bone healing, which can lead to long-lasting disability and in some cases amputation. Intravenous antibiotics administered early after injury are a well-established measure to prevent fracture-related infection (FRI), but their effectiveness is limited by poor blood flow at the fracture site and inability to achieve high local concentrations with systemic administration. Gentamicin applied locally within the open fracture wound is a promising adjunctive measure to reduce the risk of FRI after these injuries, but there are no high-quality clinical trials evaluating its use.

This will be the first randomized trial evaluating locally administered gentamicin to reduce infection in a fracture population. If efficacious, local gentamicin is likely to be a highly cost-effective preventive strategy for FRI and may ultimately be cost saving. Although these findings will originate from a low-income country, results may be generalizable to populations in both high and low-income countries and could therefore significantly reduce the global burden of open fractures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age>18 years old
  • Open tibial shaft fracture meeting the following criteria:
  • Orthopaed Trauma Association (OTA) Type 42
  • Primarily closable wound
  • Gustilo-Anderson (GA) Type I, II, or IIIA

Exclusion criteria

  • Time from injury to presentation > 48 hours
  • Time from injury to surgery > 7 days
  • Aminoglycoside allergy
  • GA IIIB or IIIC open fractures
  • Bilateral open tibial fractures
  • Severe brain (GCS<12) or spinal cord injury
  • Severe vascular injury
  • Severe burns (>10% Total Body Surface Area (TBSA) or >5% TBSA with full thickness or circumferential injury)
  • Pathologic fracture
  • History of active limb infection, ipsilaterally
  • Unlikely to complete follow-up

Treatment and study plan

Gentamicin

Drug

Liquid gentamicin administered at the open fracture site

normal saline

Drug

Normal saline administered at the open fracture site

Primary outcomes

  1. Occurrence of fracture-related infection (FRI)

    Time frame: 12 months

    Fracture-related infection is a consensus definition of infection after fracture treatment. It is diagnosed by an orthopaedic surgeon based on any of the following four diagnostic criteria: (1) fistula, sinus or wound breakdown; (2) purulent drainage from the wound or presence of pus during surgery; (3) phenotypically indistinguishable pathogens identified by culture from at least two separate deep tissue/implant specimens; or (4) presence of microorganisms in deep tissue taken during an operative intervention, as seen on histopathological examination.

    FRI diagnosis is likely to peak between 6 weeks and 6 months after surgery and has a non-normal time-to-event distribution, with incident cases rarely presenting later than 12 months after surgery. All events will be confirmed by an independent adjudication committee comprised of three masked, non-treating orthopaedic trauma surgeons.

Secondary outcomes

  1. Occurrence of nonunion

    Time frame: 12 months

    Binary outcome based on the following criteria:

    • Any unplanned reoperation for promotion of bone healing; OR
    • Modified Radiographic Union Scale for Tibia Fractures (mRUST) ≤10 at 12 months follow-up AND either: Function IndeX for Trauma (FIX-IT) score ≤11 at 12 month follow-up, OR recommendation by treating surgeon for nonunion repair surgery
  2. Occurrence of unplanned fracture-related reoperation

    Time frame: 12 months

    Occurrence of unplanned fracture-related reoperation, a binary variable, for infection, wound healing, or fracture union, excluding removal of implants for prominence/irritation. This may include but is not limited to:

    • Irrigation and debridement of surgical incisions or open fracture wounds due to infections or wound healing problems;
    • Revision wound closure for dehiscence;
    • Soft tissue coverage procedure for infected or necrotic wound;
    • Fracture delayed union or nonunion surgery (such as bone grafting or implant exchange);
    • Reoperation for hardware or prosthesis failure due to infection or bone-healing problems;
    • Amputation for infection, wound or fracture healing problem.
  3. Health-related quality-of-life (HRQOL) as measured by EQ-5D-3L (Swahili version)

    Time frame: 12 months

    The EQ-5D is a survey instrument that assesses multiple domains of quality-of-life, including mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

  4. Fracture healing by modified Radiographic Union Scale for Tibial fractures (mRUST score)

    Time frame: 12 months

    The mRUST score is based on evaluation plain radiographs of the fracture site. Each cortex is scored from 1-4 based on the degree of healing and summed resulting in an ordinal scale ranging from 4 to 16, with higher score indicating greater fracture healing.

  5. Clinical fracture healing by Function IndeX for Trauma (FIX-IT)

    Time frame: 12 months

    The FIX-IT score is an ordinal scale from 0-12 that encompasses two domains: ability to weight-bear and pain at fracture site, each scored from 0-6. Higher score indicates more clinical healing.

  6. Occurence of FRI Suggestive Criteria

    Time frame: 12 months

    Suggestive criteria are signs/symptoms of infection that do not meet criteria for definitive fracture-related infection (FRI). These include clinical signs (wound redness, fever) and radiographic signs (sequestrum), elevated serum inflammatory markers, and new onset or increased non-purulent wound drainage.

Other outcomes

  1. Adverse events

    Time frame: 12 months

    All serious and non-serious adverse events will be reported as counts for each treatment group

  2. Fold-change in creatinine level

    Time frame: 2 days

    Creatinine is a laboratory value used to assess kidney function. Creatinine levels will be measured preoperatively and 2-days postoperatively for all study participants.

Study contacts

Contact information is provided by the study sponsor or research team.

David W Shearer, MD, MPH

CONTACT

[email protected]

628-206-8812

Tigist Belaye, MPA

CONTACT

[email protected]

628-206-8812

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Muhimbili Orthopaedic Institute
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • Orthopedic Research and Education Foundation

Registry information

Official study title

A Masked, Randomized Controlled Trial Evaluating Locally-applied Gentamicin Versus Saline in Open Tibia Fractures

Acronym: GO-Tibia

Important dates

Study start
2022
Primary completion
2028
Study completion
2029
First posted
Dec 14, 2021
Registry last updated
Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.